Cargando…

Transition of Care with Dalbavancin: a Successful Cost-Saving Stewardship Program through Decreased Length of Stay

BACKGROUND: A key part of our antimicrobial stewardship program (ASP) includes interdisciplinary collaboration to develop a transition of care plan for patients needing long-term antibiotics. Many of our challenging clinical scenarios involve inpatients, who do not qualify for intravenous antibiotic...

Descripción completa

Detalles Bibliográficos
Autor principal:	Terriff, Colleen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631002/ http://dx.doi.org/10.1093/ofid/ofx163.1265

Ejemplares similares

1004. Dalbavancin Use and Associated Cost-Savings: An Update
por: Streifel, Amber C, et al.
Publicado: (2022)

1028. Dalbavancin Use in Complicated Infections and-associated Cost-Savings
por: Streifel, Amber C, et al.
Publicado: (2019)

Pharmacist-Directed Use of Dalbavancin in Acute Bacterial Skin and Skin Structure Infections to Reduce Hospital Length of Stay
por: Jones, Bruce, et al.
Publicado: (2017)

Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections
por: Poliseno, Mariacristina, et al.
Publicado: (2021)

1365. Clinical and Financial Implication of Dalbavancin Utilization on Length of Stay Avoidance in Acute Bacterial Skin and Skin Structure Infection
por: Kim, Sonia S, et al.
Publicado: (2021)

108. Evaluation of the Impact of Dalbavancin Usage on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital
por: Wei, Wenjing, et al.
Publicado: (2021)

Impact of an Antimicrobial Stewardship and Emergency Department Initiated Dalbavancin Guideline for Patients with Acute Bacterial Skin and Soft-Tissue Infections
por: Burgess, Donna R, et al.
Publicado: (2017)

A Simple Physical Therapy Algorithm Is Successful in Decreasing Skilled Nursing Facility Length of Stay and Increasing Cost Savings After Hip Fracture With No Increase in Adverse Events
por: Adrados, Murillo, et al.
Publicado: (2021)

1385. Pathway with single-dose long-acting intravenous antibiotic dalbavancin is a cost-saving alternative to usual inpatient care of acute bacterial skin and skin structure infections (ABSSSI)
por: Lovecchio, Frank, et al.
Publicado: (2022)

Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital
por: Lueking, Richard, et al.
Publicado: (2022)

Rigorous antibiotic stewardship in the hospitalized elderly population: saving lives and decreasing cost of inpatient care
por: Mauro, James, et al.
Publicado: (2021)

2437. The Impact of Healthcare Associated Infections on Costs and Lengths of Stay 2019-2023
por: Sentiff, Jennifer L, et al.
Publicado: (2023)

2902. Dalbavancin Use in Bone and Joint Infections
por: Sanikommu, Srivani, et al.
Publicado: (2023)

2764. Experience with dalbavancin in a pediatric hospital
por: Leon, Maria Deza, et al.
Publicado: (2023)

Alvimopan: A cost–effective tool to decrease cystectomy length of stay
por: Manger, Jules Powers, et al.
Publicado: (2014)

Length of Stay: An Inappropriate Readout of the Success of Enhanced Recovery Programs
por: Maessen, J. M. C., et al.
Publicado: (2008)

744. Antifungal De-escalation Strategy in ICU Patients: Clinical Success and Cost Savings
por: magira, Eleni, et al.
Publicado: (2019)

To Add or Not to Add: Would the Addition of Dalbavancin to Formulary Decrease Admissions for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)?
por: Freshwater, Dustin, et al.
Publicado: (2017)

Evaluation of Dalbavancin and Oritavancin as Cost-Effective Treatments of Acute Bacterial Skin and Skin Structure Infections in Hospitalized Patients
por: Koutsari, Christina, et al.
Publicado: (2017)

Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin
por: Loupa, Chariclia V., et al.
Publicado: (2020)

456. Dalbavancin, a Long-Acting Lipoglycopeptide Antimicrobial Agent, Reduces Length of Stay and Improves Patient Work Productivity in a Hospital Critical Pathway for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)—the ENHANCE ABSSSI Trial
por: McCarthy, Matthew W, et al.
Publicado: (2019)

Successful Establishment of an Antimicrobial Stewardship Program (ASP) for Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Nathan, Ramesh V, et al.
Publicado: (2017)

1076. Antimicrobial Stewardship Program Achieves Marked Decrease in the use of Vancomycin in a Veterans Hospital
por: Ford, Florence M, et al.
Publicado: (2019)

224. Cost Analysis of a Significant Decrease in Vancomycin Use as a Result of an Antimicrobial Stewardship Intervention
por: Hodgson, Hayley, et al.
Publicado: (2018)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

438. Dalbavancin Clinical Experience at an NCI Designated Cancer Center
por: McDaneld, Patrick, et al.
Publicado: (2019)

225. Dalbavancin Usage in Patients Who Inject Drugs (PWID)
por: Patel, Kaya, et al.
Publicado: (2023)

733. The attributable mortality, length of stay, and healthcare costs of methicillin-resistant Staphylococcus aureus infections in Singapore
por: Cai, Yiying, et al.
Publicado: (2023)

1251. Strengthening Antimicrobial Stewardship Programs through Public Health Support
por: Kriengkauykiat, Jane, et al.
Publicado: (2023)

625. The Hidden Cost of Dalbavancin: OPAT-RN Time Spent on Coordination for Patients with Substance Use Disorder
por: Douglass, Alyse, et al.
Publicado: (2021)

599. Dalbavancin Utilization in Rural Healthcare Setting: A Single Center Three Years’ Experience
por: AlSalman, Ahmad, et al.
Publicado: (2020)

1828. Dalbavancin Utilization and Associated Clinical Outcomes: A Case-Series
por: Greckel, Meagan N, et al.
Publicado: (2022)

2765. Dalbavancin for challenging left ventricular assist device driveline infections
por: Doligalski, Christina, et al.
Publicado: (2023)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

122. Dalbavancin Use in Patients with Substance Use Disorders
por: Streifel, Amber C, et al.
Publicado: (2020)

614. Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2021)

Antimicrobial Activity of Dalbavancin Tested against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from United States (US) Medical Centers
por: Sader, Helio S, et al.
Publicado: (2017)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

1629. Targeted Antimicrobial Use Admission Provides an Actionable Denominator for Antimicrobial Stewardship Programs Evaluating Inpatient Length of Therapy
por: Dyer, April, et al.
Publicado: (2018)

Length of stay and reason for admission in an adolescents inpatient unit
por: Taracena Cuerda, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a3o3v89c16ecbqna28rmmuda2i